Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes
Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop, and methods of using these structures and computer systems are also disclosed.
1. An isolated nucleic acid comprising a nucleotide sequence encoding a wild type HIV-1 gp120 polypeptide, or immunogenic fragment thereof, comprising substitutions of cysteines for the amino acids in at least one of residue pairs 96 and 275; 109 and 428; 123 and 431; and 231 and 267, and amino acid substitutions at positions 257 and 375, wherein the polypeptide, or fragment thereof further comprises a tryptophan at position 95 if the polypeptide, or fragment thereof comprises cysteines at residue pairs 96 and 275, and wherein the residue numbers correspond to amino acid positions in the amino acid sequence set forth as SEQ ID NO: 27.
2. The isolated nucleic acid of claim 1 , comprising a nucleotide sequence set forth as one of SEQ ID NOs: 4-9, 11-18, or 26 or a degenerate variant thereof
3. The isolated nucleic acid of claim 2 operably linked to a promoter.
4. A vector comprising the nucleic acid of claim 3 .
5. An isolated host cell comprising the vector of claim 4 .
6. A composition comprising a nucleic acid molecule of claim 1 and a carrier.
7. A method for generating an immune response in a subject, comprising administering to the subject the nucleic acid molecule of claim 1 , thereby generating the immune response.
8. The method of claim 7 , further comprising administering to the subject a polypeptide or a nucleic acid molecule encoding:
a) monomeric or trimeric gp140 of HIV envelope polypeptide;
b) an unmodified monomeric or trimeric gp120 of HIV envelope polypeptide; or
c) any combination of a-b, above.
9. An isolated nucleic acid molecule comprising the nucleotide sequence encoding the amino acid sequence set forth as SEQ ID NO: 2.
10. The isolated nucleic acid of claim 9 , operably linked to a promoter.
11. A vector comprising the nucleic acid of claim 10 .
12. An isolated host cell comprising the vector of claim 11 .
13. A composition comprising the isolated nucleic acid molecule of claim 9 and a carrier.
14. The method of claim 7 , further comprising administering a polypeptide or a nucleic acid expressing a polypeptide selected from the group consisting of:
a) monomeric or trimeric gp140 of HIV envelope polypeptide;
b) an unmodified monomeric or trimeric gp120 of an HIV envelope polypeptide;
c) a soluble form of CD4; or
d) any combination of a-c, above.
15. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence encodes gp120 Hxbc core of SEQ ID NO: 20 having substitutions of cysteines for the amino acids at positions 96, 109, 275, and 428.
16. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence encodes gp120 Hxbc core of SEQ ID NO: 20 having substitutions of cysteines for the amino acids at positions 96, 109, 275, and 428, a tryptophan for the methionine at position 95, a serine for the threonine at position 257, a tryptophan for the serine at position 375, and a methionine for the alanine at position 433.
17. The isolated nucleic acid of claim 16 , comprising the nucleic acid sequence set forth as SEQ ID NO: 10 or a degenerate variant thereof.
18. The isolated nucleic acid of claim 16 , comprising the nucleic acid sequence set forth as SEQ ID NO: 10.
19. The isolated nucleic acid of claim 15 , operably linked to a promoter.
20. A vector comprising the nucleic acid of claim 19 .
21. A isolated host cell comprising the vector of claim 20 .
22. The isolated nucleic acid of claim 16 , operably linked to a promoter.
23. A vector comprising the nucleic acid of claim 22 .
24. A isolated host cell comprising the vector of claim 23 .